-
公开(公告)号：WO2019133747A1
公开(公告)日：2019-07-04
申请号：PCT/US2018/067740
申请日：2018-12-27
发明人： BARNHART, Bryan C. , DEVAUX, Brigitte , YAMNIUK, Aaron P. , OKADA, Shannon L. , STEVENS, Brenda L. , WEST, James William
CPC分类号： C07K16/2878 , A61P31/12 , A61P35/00 , C07K2317/51 , C07K2317/515 , C07K2317/75 , C07K2317/94
摘要： Provided herein are agonistic antibodies, or antigen binding portions thereof, that bind to human CD40 and comprise improved heavy and light chain variable regions that impart improved yield and reduced aggregation. The invention also provides methods of treatment of cancer or chronic infection by administering the antibodies of the invention to a subject in need thereof.
-
2.发明申请
公开(公告)号：WO2018107116A1
公开(公告)日：2018-06-14
申请号：PCT/US2017/065455
申请日：2017-12-08
发明人： LIU, David
IPC分类号： A61K38/00 , A61K39/00 , A61K39/395 , A61K47/48 , A61K47/68
CPC分类号： C07K16/28 , A61K38/00 , A61K47/6803 , A61K47/6849 , A61K47/6871 , A61K2039/505 , C07K16/24 , C07K16/40 , C07K2317/24 , C07K2317/515 , C07K2317/52 , C07K2317/524 , C07K2317/56 , C07K2317/71 , C07K2317/732 , C07K2317/734 , C07K2317/94
摘要： This application provides antibodies, immunoreactive fragments thereof, having modifications such as amino acid deletions and/or substitutions within their constant region (Fc), and antibody drug conjugates (ADCs) comprising said modified antibodies or immunoreactive fragments, having effective anti-cancer activity while exhibiting improved pharmacokinetic and toxicity profiles.
-
3.发明申请PD-L1 Specific Monoclonal Antibodies for Disease Treatment and Diagnosis 审中-公开用于疾病治疗和诊断的PD-L1特异性单克隆抗体
公开(公告)号：WO2017218435A1
公开(公告)日：2017-12-21
申请号：PCT/US2017/037076
申请日：2017-06-12
发明人： WANG, Aijun , SHANEBECK, Kurt , HE, Donggou , YAO, Chen , LI, Lu , XIA, Fang , LU, Yuefeng , LU, Jian-Feng , YANG, Lan
IPC分类号： A61K39/395 , C07K16/28 , C07K16/46 , C12N15/13
CPC分类号： C07K16/2827 , A61K2039/505 , A61P35/00 , C07K2317/24 , C07K2317/31 , C07K2317/51 , C07K2317/515 , C07K2317/92
摘要： The present invention relates to compositions and methods for immunotherapy of a subject afflicted with diseases such as cancer, an infectious disease, or a neurodegenerative disease, which methods comprise administering to the subject a composition comprising a therapeutically effective amount of an anti-PD-L1 antibody or portion thereof that potentiates an endogenous immune response, either stimulating the activation of the endogenous response or inhibiting the suppression of the endogenous response.
摘要翻译： 本发明涉及用于患有诸如癌症，传染病或神经退行性疾病等疾病的受试者的免疫治疗的组合物和方法，所述方法包括向所述受试者施用包含治疗有效量的组合物 增强内源性免疫应答的抗PD-L1抗体或其部分的量，可以刺激内源性应答的激活或抑制内源性应答的抑制。
-
公开(公告)号：WO2017058859A1
公开(公告)日：2017-04-06
申请号：PCT/US2016/054089
申请日：2016-09-28
申请人： CELGENE CORPORATION
发明人： BENNETT, Brydon , CHAMBERLAIN, Philip, Paul , HARIHARAN, Kandasamy , JACKSON, Pilgrim , KEHRY, Marilyn , KHATTRI, Roli , LEUNG, Monica , MORRISON, Lisa , SUN, Jeonghoon , TORRES, Sanaa , CHAN, Henry, H.
IPC分类号： A61K39/395 , C07K16/18 , C07K16/28
CPC分类号： C07K16/2818 , A61K2039/505 , C07K2317/33 , C07K2317/34 , C07K2317/51 , C07K2317/515 , C07K2317/52 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/567 , C07K2317/732 , C07K2317/734 , C07K2317/76 , C07K2317/92
摘要： Provided herein are compositions, methods and uses involving antibodies that specifically bind to Programmed Death-1 (PD-1) and modulate the expression and/or activity of PD-1.
摘要翻译： 本文提供涉及特异性结合程序性死亡-1（PD-1）并调节PD-1的表达和/或活性的抗体的组合物，方法和用途。
-
5.发明申请BISPECIFIC ANTI-HUMAN CD20/HUMAN TRANSFERRIN RECEPTOR ANTIBODIES AND METHODS OF USE 审中-公开双重抗人CD20 /人转铁蛋白受体抗体及其使用方法
公开(公告)号：WO2017055542A1
公开(公告)日：2017-04-06
申请号：PCT/EP2016/073413
申请日：2016-09-30
发明人： DUERR, Harald , FENN, Sebastian , GOEPFERT, Ulrich , IMHOF-JUNG, Sabine , KLEIN, Christian , LARIVIERE, Laurent , MOLHOJ, Michael , REGULA, Joerg Thomas , RUEGER, Petra , SCHAEFER, Wolfgang
IPC分类号： C07K16/28
CPC分类号： C07K16/2887 , C07K16/2881 , C07K2317/31 , C07K2317/515 , C07K2317/522 , C07K2317/55
摘要： Herein are provided bispecific anti-human CD20/human transferrin receptor antibodies and methods of using the same.
摘要翻译： 本文提供双特异性抗人CD20 /人转铁蛋白受体抗体及其使用方法。
-
6.发明申请CD33XCD3 BISPECIFIC T CELL ACTIVATING ANTIGEN BINDING MOLECULES 审中-公开CD33XCD3 BISPECIFIC T细胞活化抗原结合分子
公开(公告)号：WO2017055318A1
公开(公告)日：2017-04-06
申请号：PCT/EP2016/073046
申请日：2016-09-28
发明人： KLEIN, Christian , SCHAEFER, Wolfgang , KLOSTERMANN, Stefan , IMHOF-JUNG, Sabine , MOLHOJ, Michael , REGULA, Joerg Thomas , FAUTI, Tanja , DUMONTET, Charles , UMANA, Pablo , BACAC, Marina , FREIMOSER-GRUNDSCHOBER, Anne
CPC分类号： C07K16/3061 , A61K2039/505 , A61K2039/57 , C07K16/2803 , C07K16/2809 , C07K16/468 , C07K2317/24 , C07K2317/31 , C07K2317/35 , C07K2317/515 , C07K2317/52 , C07K2317/522 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/66 , C07K2317/71 , C07K2317/73 , C07K2317/75 , C07K2317/92 , C07K2319/00
摘要： The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.
摘要翻译： 本发明一般涉及用于T细胞活化和对特异性靶细胞的重新定向的新型双特异性抗原结合分子。 此外，本发明涉及编码这种双特异性抗原结合分子的多核苷酸，以及包含这种多核苷酸的载体和宿主细胞。 本发明还涉及用于产生本发明的双特异性抗原结合分子的方法以及在治疗疾病中使用这些双特异性抗原结合分子的方法。
-
公开(公告)号：WO2017055291A1
公开(公告)日：2017-04-06
申请号：PCT/EP2016/073008
申请日：2016-09-27
IPC分类号： A61K39/395 , A61K45/00 , C07K16/22 , A61P35/00
CPC分类号： C07K16/22 , A61K31/506 , A61K31/519 , A61K38/08 , A61K38/1774 , A61K39/3955 , A61K39/39558 , C07K2317/51 , C07K2317/515 , C07K2317/565 , C07K2317/76 , A61K2300/00
摘要： The invention describes anti-cancer therapies comprising using a 3G-EGFR inhibitor and an anti-IGF antibody, each as described herein.
摘要翻译： 本发明描述了包括使用3G-EGFR抑制剂和抗IGF抗体的抗癌疗法，其各自如本文所述。
-
8.发明申请ANTIBODIES TARGETING BONE MORPHOGENETIC PROTEIN 9 (BMP9) AND METHODS THEREFOR 审中-公开靶向骨形态蛋白9（BMP9）的抗体及其方法
公开(公告)号：WO2016193872A3
公开(公告)日：2017-03-30
申请号：PCT/IB2016053095
申请日：2016-05-26
申请人： NOVARTIS AG , CHEN ZIJUN , DENG SUJUN , HE YUN , HUANG DAGANG , KUGLER MARKUS , LI QIAN , LU CHRIS XIANGYANG , LUO XIAO , SHAN YONGQIANG , TISSOT-DAGUETTE KATHRIN ULRIKE , WU JING
发明人： CHEN ZIJUN , DENG SUJUN , HE YUN , HUANG DAGANG , KUGLER MARKUS , LI QIAN , LU CHRIS XIANGYANG , LUO XIAO , SHAN YONGQIANG , TISSOT-DAGUETTE KATHRIN ULRIKE , WU JING
IPC分类号： C07K16/22 , A61K39/00 , A61K39/395 , A61K45/06
CPC分类号： C07K16/22 , A61K31/155 , A61K31/355 , A61K31/4439 , A61K31/4725 , A61K31/497 , A61K31/513 , A61K31/522 , A61K31/575 , A61K31/675 , A61K31/7072 , A61K39/3955 , A61K45/06 , A61K2039/505 , C07K2317/21 , C07K2317/24 , C07K2317/33 , C07K2317/34 , C07K2317/51 , C07K2317/515 , C07K2317/52 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/73 , C07K2317/76 , C07K2317/90 , C07K2317/92 , C07K2317/94 , A61K2300/00
摘要： The present invention relates to isolated antibodies and antigen-binding fragments thereof which bind human BMP9 and compositions and methods of use thereof.
摘要翻译： 本发明涉及结合人BMP9的分离的抗体及其抗原结合片段及其组合物及其使用方法。
-
9.发明申请METHODS OF TREATING PATIENTS HAVING MUTATIONS IN THE EXTRACELLULAR DOMAIN OF EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) WITH A COMBINATION OF THREE FULLY HUMAN MONOCLONAL ANTI-EGFR ANTIBODIES 审中-公开在具有三种完全人类单克隆抗EGFR抗体的组合的EPIDERMAL生长因子受体（EGFR）的细胞外区域中进行突变的患者的治疗方法
公开(公告)号：WO2016172584A9
公开(公告)日：2017-03-09
申请号：PCT/US2016028987
申请日：2016-04-22
发明人： ARENA SABRINA , BARDELLI ALBERTO , KEARNS JEFFREY DAVID , WOLF BENI B , NERING RACHEL C , WANG HONGFANG
IPC分类号： C07K16/28 , A61K39/395 , A61P35/00 , C07K16/30 , G01N33/574
CPC分类号： C07K16/2863 , A61K2039/507 , A61K2039/55 , C07K16/30 , C07K16/3046 , C07K2317/21 , C07K2317/33 , C07K2317/51 , C07K2317/515 , C07K2317/56 , C07K2317/565 , C07K2317/73 , C07K2317/76 , C12Q1/6886 , C12Q2600/106 , C12Q2600/156
摘要： Provided herein are methods of treating an epidermal growth factor receptor (EGFR) extracellular domain (ECD) mutant cancer in a human patient by administering to the patient an oligoclonal anti-epidermal growth factor receptor (anti-EGFR) antibody combination (e.g., MM-151, comprising a first monoclonal antibody (P1X), a second monoclonal antibody (P2X), and a third monoclonal antibody (P3X),wherein P1X, P2X and P3X are in a 2:2: 1 molar ratio). In one embodiment, the cancer comprises at least one mutation in the extracellular domain of EGFR selected from the group consisting of EGFR R451C, S464L, K467T, G465R, G465E, 1491M, and S492R.
摘要翻译： 本文提供了通过向患者施用寡克隆抗表皮生长因子受体（抗EGFR）抗体组合（例如MM-1），治疗人类患者中表皮生长因子受体（EGFR）细胞外结构域（EGF）突变体癌症的方法， 151，包含第一单克隆抗体（P1X），第二单克隆抗体（P2X）和第三单克隆抗体（P3X），其中P1X，P2X和P3X的摩尔比为2:2:1）。 在一个实施方案中，癌症包括选自EGFR R451C，S464L，K467T，G465R，G465E，1491M和S492R的EGFR细胞外结构域中的至少一个突变。
-
公开(公告)号：WO2017004149A1
公开(公告)日：2017-01-05
申请号：PCT/US2016/040007
申请日：2016-06-29
CPC分类号： C07K16/468 , C07K16/241 , C07K16/244 , C07K16/2803 , C07K16/30 , C07K2317/31 , C07K2317/51 , C07K2317/515 , C07K2317/52 , C07K2317/526 , C07K2317/53 , C07K2317/622 , C07K2317/64 , C07K2317/92 , C07K2317/94 , C07K2319/00
摘要： This invention generally relates to multi-specific binding proteins. The invention also relates to methods of making such proteins and to methods of using such proteins. Pharmaceutical compositions and kits comprising such proteins are also disclosed.
摘要翻译： 本发明一般涉及多特异性结合蛋白。 本发明还涉及制备这些蛋白质的方法和使用这些蛋白质的方法。 还公开了包含这种蛋白质的药物组合物和试剂盒。
-
-
-
-
-
-
-
-
-
搜索结果
504 条记录 (耗时 0.05 秒)
